Abstract

Renal cell carcinoma (RCC) is the most common and a highly aggressive type of malignant renal tumor. In this manuscript, we aim to identify and integrate the optimal discriminating morphological, textural, and functional features that best describe the malignancy status of a given renal tumor. The integrated discriminating features may lead to the development of a novel comprehensive renal cancer computer-assisted diagnosis (RC-CAD) system with the ability to discriminate between benign and malignant renal tumors and specify the malignancy subtypes for optimal medical management. Informed consent was obtained from a total of 140 biopsy-proven patients to participate in the study (male = 72 and female = 68, age range = 15 to 87 years). There were 70 patients who had RCC (40 clear cell RCC (ccRCC), 30 nonclear cell RCC (nccRCC)), while the other 70 had benign angiomyolipoma tumors. Contrast-enhanced computed tomography (CE-CT) images were acquired, and renal tumors were segmented for all patients to allow the extraction of discriminating imaging features. The RC-CAD system incorporates the following major steps: (i) applying a new parametric spherical harmonic technique to estimate the morphological features, (ii) modeling a novel angular invariant gray-level co-occurrence matrix to estimate the textural features, and (iii) constructing wash-in/wash-out slopes to estimate the functional features by quantifying enhancement variations across different CE-CT phases. These features were subsequently combined and processed using a two-stage multilayer perceptron artificial neural network (MLP-ANN) classifier to classify the renal tumor as benign or malignant and identify the malignancy subtype as well. Using the combined features and a leave-one-subject-out cross-validation approach, the developed RC-CAD system achieved a sensitivity of , a specificity of , and Dice similarity coefficient of in differentiating malignant from benign tumors, as well as an overall accuracy of in discriminating ccRCC from nccRCC. The diagnostic abilities of the developed RC-CAD system were further validated using a randomly stratified 10-fold cross-validation approach. The obtained results using the proposed MLP-ANN classification model outperformed other machine learning classifiers (e.g., support vector machine, random forests, relational functional gradient boosting, etc.). Hence, integrating morphological, textural, and functional features enhances the diagnostic performance, making the proposal a reliable noninvasive diagnostic tool for renal tumors.

Highlights

  • Renal cancer is one of the most common malignancies, being the sixth most prevalent type of cancer among men and the eighth most prevalent among women

  • We developed renal cancer computer-assisted diagnosis (RC-CAD), a two-stage system for comprehensive computer-assisted diagnosis of renal cancer based on Contrast-enhanced computed tomography (CE-CT) imaging

  • It is worth noting that this paper extends our recent work [39] with the following substantial modifications: (i) increasing the sample size from 105 (70 Renal cell carcinoma (RCC) vs. 35 AML) to 140 renal tumors (70 RCC vs. 70 AML) to ensure data balancing and to avoid any possible classification bias towards the majority class, (ii) applying a new parametric spherical harmonic technique to estimate the morphological features from the segmented renal tumors to capture the surface complexity/irregularity between different types of renal tumors, (iii) integrating/concatenating the estimated morphological features with the firstand second-order textural features and functional features, and (iv) modeling a two-stage classification using a multilayer perceptron artificial neural network (MLP-Artificial neural networks (ANNs)) whose inputs comprise all the aforementioned discriminant features

Read more

Summary

Introduction

Renal cancer is one of the most common malignancies, being the sixth most prevalent type of cancer among men and the eighth most prevalent among women. For the past several decades, an increasing number of new patients have been diagnosed with renal cancer. The year 2020 saw approximately 74,000 diagnoses of renal cancer in the United. States [1,2], and 15,000 patients are expected to have died from renal cancer in that same time period [1,2]. Two thirds of the time, renal cancer is diagnosed before it has metastasized, in which case the 5 y survival rate is 93%. In the worst case of metastasis to distant parts of the body, the 5 y survival rate is a mere 12% [1,2]. The National Cancer Institute had an approximated cost estimate of $5.1 billion for renal cancer care in the United States by the end of 2020 [3]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call